BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Find MoreGigantism is excessive production of Growth Hormone (GH) in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin-like growth factor I (IGF-I) while the epiphyseal growth plates are open during c...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!